OncoMatch/Clinical Trials/NCT06749691

Liposomal Irinotecan and Apatinib in ES-SCLC

Is NCT06749691 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Liposomal Irinotecan and Apatinib for small cell lung cancer extensive stage.

Phase 2RecruitingSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06749691Data as of May 2026

Treatment: Liposomal Irinotecan and Apatinib — The purpose of this study is to observe the efficacy and safety of liposomal irinotecan combined with apatinib in the treatment of extensive stage small cell lung cancer progressed from first-line regimen.

Check if I qualify

Extracted eligibility criteria

Cancer type

Small Cell Lung Cancer

Disease stage

Required: Stage IV

at least one measurable lesion (according to RECIST V 1.1)

Prior therapy

Max 2 prior lines

Min 1 prior line

Must have received: any systemic therapy — first-line or second-line

For patients who have failed first-line or second-line treatment.

Cannot have received: VEGF or VEGFR-targeted therapy (ranibizumab, fipronib, apatinib, anlotinib, lenvatinib, sunitinib, sorafenib)

Have received any systemic treatment targeting VEGF or VEGFR in the past, such as treatment with anti angiogenic drugs such as ranibizumab, fipronib, apatinib, anlotinib, lenvatinib, sunitinib, sorafenib.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify